# Mendra

**Canonical:** https://apis.io/providers/mendra/  
**Website:** https://mendra.com  
**APIs profiled:** 0

Mendra is an AI-native biopharma company focused on developing breakthrough medicines for rare and ultra-rare pediatric diseases. It partners with R&D-stage biotech companies to accelerate clinical development and commercialization, handling regulatory, clinical, and reimbursement strategy while prioritizing the needs of patients and families. Founded by a team with experience from BioMarin, Palantir, and other pharma and biotech companies, Mendra launched with an $82 million Series A round and is backed by 8VC and Wing Venture Capital. The company operates a corporate marketing website and publishes no public API, developer portal, SDK, or technical documentation.

## Kin Score — 2.2 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 2.2).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 0.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Biopharma, Rare Diseases, Pharmaceuticals, Artificial Intelligence, Healthcare, Drug Development, Clinical Development

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/mendra/). Scores are computed from the provider's own public artifacts under a published rubric.